Tumor PD-L1 expression, immune cell correlates and PD-1+ lymphocytes in sentinel lymph node melanoma metastases. (Q41320696)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26403784%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

title

Tumor PD-L1 expression, immune cell correlates and PD-1+ lymphocytes in sentinel lymph node melanoma metastases (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26403784%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26403784%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

Hojabr Kakavand

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26403784%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

Georgina V. Long

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26403784%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

author name string

Ricardo E Vilain

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26403784%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

James S Wilmott

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26403784%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

Hazel Burke

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26403784%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

Jennifer H Yearley

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26403784%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

John F Thompson

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26403784%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

Peter Hersey

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26403784%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

language of work or name

1 reference

25 September 2015

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26403784%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26403784%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

volume

28

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26403784%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

issue

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26403784%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

page(s)

1535-1544

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26403784%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1038/modpathol.2015.110

24 February 2020

exact match

0 references

cites work

Final trial report of sentinel-node biopsy versus nodal observation in melanoma

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2015.110

Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2015.110

Interferon alpha adjuvant therapy in patients with high-risk melanoma: a systematic review and meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2015.110

Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2015.110

A pooled analysis of eastern cooperative oncology group and intergroup trials of adjuvant high-dose interferon for melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2015.110

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2015.110

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2015.110

Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2015.110

Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2015.110

Improved overall survival in melanoma with combined dabrafenib and trametinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2015.110

Combined vemurafenib and cobimetinib in BRAF-mutated melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2015.110

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2015.110

Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2015.110

PD-1 and its ligands in tolerance and immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2015.110

Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2015.110

B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2015.110

PD-L2 is a second ligand for PD-1 and inhibits T cell activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2015.110

B7-DC, a new dendritic cell molecule with potent costimulatory properties for T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2015.110

Expression of programmed death 1 ligands by murine T cells and APC

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2015.110

Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2015.110

Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2015.110

Selective BRAF inhibitors induce marked T-cell infiltration into human metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2015.110

PD-L1 Expression and Tumor-Infiltrating Lymphocytes Define Different Subsets of MAPK Inhibitor-Treated Melanoma Patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2015.110

PD-1 blockade induces responses by inhibiting adaptive immune resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2015.110

Sentinel-node biopsy or nodal observation in melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2015.110

Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2015.110

Overall survival and PD-L1 expression in metastasized malignant melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2015.110

Nivolumab in previously untreated melanoma without BRAF mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2015.110

Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2015.110

Tumor-infiltrating lymphocyte grade is an independent predictor of sentinel lymph node status and survival in patients with cutaneous melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2015.110

Foxp3 expressing CD4+CD25(high) regulatory T cells are overrepresented in human metastatic melanoma lymph nodes and inhibit the function of infiltrating T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2015.110

PD-L1 expression in melanoma shows marked heterogeneity within and between patients: implications for anti-PD-1/PD-L1 clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2015.110

Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death

21 January 2018

2 references

12 December 2020

https://api.crossref.org/works/10.1038%2FMODPATHOL.2015.110

7 January 2021

inferred from DOI database lookup

Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma

1 reference

12 December 2020

Final version of 2009 AJCC melanoma staging and classification

1 reference

12 December 2020

Tumor infiltrating lymphocytes in lymph node melanoma metastases: a histopathologic prognostic indicator and an expression of local immune response

1 reference

12 December 2020

10.1038/MODPATHOL.2015.110

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26403784%20AND%20SRC:MED&resulttype=core&format=json

Dimensions Publication ID

24 February 2020

0 references

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26403784%20AND%20SRC:MED&resulttype=core&format=json